The New York Department of Health granted conditional approval to Rosetta Genomics Ltd.'s (Nasdaq: ROSG) multiple fluorescence in situ hybridization tests for detection of amplifications or rearrangements of DNA in hematologic cancers. The stock price gained 21 cents to $1.35.
Approval granted to Rosetta Genomics
June 21, 2016 at 13:10 PM EDT
